Creso increases supply of hemp protein to large Slovakian bakery
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Leading supplier of therapeutic grade nutraceutical cannabis and hemp products, Creso Pharma (ASX: CPH), has delivered its second shipment of hemp protein to one of Slovakia’s largest bakeries, Pekarne Liptovsky Hradok,s.r.o. (PLH).
The 700 kilogram shipment followed the delivery of 500 kilograms in mid-August, and has effectively created an additional revenue stream for the vertically integrated group.
CPH’s Hemp Industries division is looking to forge a long-term relationship with PLH, resulting in increased shipments of hemp protein and other hemp seed based products.
However, it is early stages in this relationship, so investors should seek professional financial advice for further information if considering this stock for their portfolio.
Having been operating nearly 80 years and traditionally involved in the production of wafers, biscuits, vanilla and cinnamic sugar, PLH has been transformed into a company that is increasingly focused on producing products that assist in treating health conditions such as diabetes, celiac disease and lactose intolerance.
Consequently, a relationship between the broader Creso Pharma group and PLH would be a good fit given the former’s focus on developing therapeutic grade nutraceutical products for humans and animals.
PLH an established player with access to wide ranging markets
Importantly, PLH has access to a broad range of markets, and it currently exports products into Yemen, Poland, Hungary, Romania and the Czech Republic.
Hemp seeds and products made from hemp seeds are experiencing an increase in demand in the food, food supplement, health and sports markets due to their high content of amino acids, omega acids, protein and other beneficial substances. Due to the high nutrition content they are now being characterised as a super-food.
In response to this development, CPH’s executive chairman, Boaz Wachtel said, “We are very pleased with the market reception of Hemp Industries’ new protein product line and it is important to note that the market potential for hemp protein sales in the European Union is significant”.
You can read more from Wachtel in a recent interview conducted by the world’s number one hemp magazine, Hemp Today.
Hemp protein provides additional revenue stream
Wachtel highlighted the fact that the current revenues generated by Hemp Industries’ CBD product line, CBDium is now augmented by additional revenues from the sale of the new hemp protein product line.
This news comes only a fortnight after CPH negotiated an important Letter of Intent (LOI) with Canadian medical cannabis group CanniMed which included the appointment of CPH as preferred distributor in the European Union for all CanniMed medical cannabis products.
Consequently, it is clear that the company is establishing a strong presence in Europe, and the relationship with PLH strengthens its position in the region.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
